EPRX Eupraxia Pharmaceuticals Inc.
USHealthcareAs of 2026-07-10 16:00
Why EPRX matters now
Eupraxia Pharmaceuticals Inc. (EPRX) is a US stock in Healthcare. The latest InvestLog snapshot shows $6.68 with -3.33% on the session and $223.6M in market capitalization; recent performance reads 1-month +3.02% and YTD -14.17%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-12.5M, and EPS of $-0.23. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -14.0%.
The latest indexable market news headline is "Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $19.00. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.63
P/S
0.00
EV/EBITDA
-3.89
DCF Value
$1.44
FCF Yield
-14.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-50.8%
ROA
-29.0%
ROIC
-32.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-12.5M | $-0.23 |
| Q4 2025 | $0.00 | $-16.7M | $-0.34 |
| FY 2025 | $0.00 | $-53.9M | $-1.05 |
| Q3 2025 | $0.00 | $-4.6M | $-0.19 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$19.00
Target (Median)
$19.00
Target Range
$19.00 - $19.00
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
1.48
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology firm dedicated to the innovation, advancement, and commercialization of new technologies within the biotech sector. Its primary therapeutic focus revolves around a portfolio of product candidates, notably EP-104IAR, which is currently undergoing a Phase III clinical trial to address significant unmet medical needs, particularly offering pain relief for knee osteoarthritis. Another key candidate, EP-104GI, is progressing through Phase II trials for the treatment of eosinophilic esophagitis. Additionally, EP-104 is in preclinical development, exploring its potential for various inflammatory joint conditions, benign esophageal strictures, and applications via epidural delivery. Beyond these, the company is also developing drug candidates in the field of oncology. Originally established as Plaza Capital Partners Inc., the company rebranded to Eupraxia Pharmaceuticals Inc. in May 2012. Incorporated in 2011, Eupraxia Pharmaceuticals Inc. operates from its headquarters in Victoria, Canada.